$-0.19 EPS Expected for Compugen Ltd. (CGEN)

October 13, 2018 - By Richard Conner

Compugen Ltd. (NASDAQ:CGEN) Logo

Analysts expect Compugen Ltd. (NASDAQ:CGEN) to report $-0.19 EPS on November, 6.They anticipate $0.00 EPS change or 0.00 % from last quarter’s $-0.19 EPS. After having $-0.19 EPS previously, Compugen Ltd.’s analysts see 0.00 % EPS growth. The stock decreased 4.29% or $0.15 during the last trading session, reaching $3.35. About 498,899 shares traded or 154.15% up from the average. Compugen Ltd. (NASDAQ:CGEN) has risen 14.93% since October 13, 2017 and is uptrending. It has underperformed by 0.69% the S&P500.

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel and Europe. The company has market cap of $191.61 million. The company's pipeline primarily includes early and preclinical stage immuno-oncology programs based on novel drug targets, such as immune checkpoint and myeloid protein target candidates to harness the immune system to provide treatment solutions in the areas of unmet medical needs in various cancer types and patient populations. It currently has negative earnings. The Company’s antibody drug conjugate target candidates comprise CGEN-15001T, CGEN-15022, CGEN-15029, and CGEN-15137 for oncology; and therapeutic proteins include CGEN-15001, a fusion protein for autoimmune diseases, as well as CGEN myeloid target.

More notable recent Compugen Ltd. (NASDAQ:CGEN) news were published by: Streetinsider.com which released: “Pre-Open Movers 10/11: (CGEN) (HEAR) (CRSP) Higher; (ATOM) (SHLD) (FLR) Lower (more…)” on October 11, 2018, also Seekingalpha.com with their article: “Compugen Ltd. (CGEN) Compugen and Bristol-Myers Squibb Clinical Collaboration and Equity Investment Conference …” published on October 12, 2018, Seekingalpha.com published: “Compugen receives milestone payment in cancer immunotherapy collaboration with Bayer” on September 20, 2018. More interesting news about Compugen Ltd. (NASDAQ:CGEN) were released by: Marketwatch.com and their article: “US stocks close lower as Dow drops nearly 1400 points in 2 days” published on October 11, 2018 as well as Benzinga.com‘s news article titled: “Don’t Fixate On Market Woes, Just Make Your Trades” with publication date: October 12, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Market News

>